NCT05921916View on ClinicalTrials.gov

Study to Assess the Safety and Tolerability of MBF-118 in Healthy Volunteers

PHASE1CompletedINTERVENTIONAL
Enrollment

56

Participants

Timeline

Start Date

July 3, 2020

Primary Completion Date

September 6, 2022

Study Completion Date

September 6, 2022

Conditions
Cancer
Interventions
DRUG

MBF-118 oral capsules

MBF-118 oral capsules PPAR gamma receptor partial agonist

DRUG

Placebo oral capsule

Placebo oral capsule solid microcrystalline cellulose

Trial Locations (1)

Unknown

CIM-Sant Pau Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau, Barcelona

Sponsors

Lead Sponsor

Medibiofarma S.L.
All Listed Sponsors
lead

Medibiofarma S.L.

INDUSTRY

NCT05921916 - Study to Assess the Safety and Tolerability of MBF-118 in Healthy Volunteers | Biotech Hunter | Biotech Hunter